Alex Ralph (thetimes.com)
Company was spun out of the Beckley Foundation which has its origins in an aristocrat’s Tudor hunting lodge
A psychedelic drugs company whose lead asset is based on a chemical found in the Sonoran Desert toad, and whose origins lie with an Oxfordshire aristocrat, has been acquired by Eli Lilly for up to $3.8 billion.
AtaiBeckley, listed on New York’s Nasdaq, has agreed a sale to the US pharma group a few months after the market was lifted by President Trump’s executive order directing regulators to speed up reviews of psychedelic therapies and to increase federal research funding.
The company was created a year ago through the $390 million all-share combination between Atai Life Sciences and Beckley Psytech. The latter was spun out of the Beckley Foundation, an institute founded in 1998 to research the effects of psychoactive drugs that was started by the late Amanda Feilding, the Countess of Wemyss and March. It was registered at Beckley Park, the family home, a Tudor hunting lodge near Oxford.
Cosmo Feilding Mellen, 41, her son, who was chief executive of Beckley Psytech, remained a shareholder in AtaiBeckley following last year’s combination, holding a stake of about 2 per cent, according to FactSet data. Lilly’s takeover values his stake at more than $50 million.
Early investors in Beckley Psytech, which was incorporated in 2018, included Jim Mellon, the businessman and investor, and Richard Reed, a co-founder of Innocent Drinks.